Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT03854227

Public ClinicalTrials.gov record NCT03854227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 (PRMT5 INHIBITOR) IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, ESOPHAGEAL CANCER, ENDOMETRIAL CANCER, CERVICAL CANCER AND BLADDER CANCER

Study identification

NCT ID
NCT03854227
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
54 participants

Conditions and interventions

Interventions

  • PF-06939999 dose escalation Drug
  • PF-06939999 monotherapy Drug
  • PF-06939999 in combination with docetaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 13, 2019
Primary completion
Apr 26, 2022
Completion
Apr 26, 2022
Last update posted
Jan 12, 2025

2019 – 2022

United States locations

U.S. sites
22
U.S. states
8
U.S. cities
13
Facility City State ZIP Site status
Scottsdale Healthcare Hospitals d/b/a HonorHealth Scottsdale Arizona 85258
Virginia G. Piper Cancer Pharmacy Scottsdale Arizona 85258
Keck Hospital of USC Los Angeles California 90033
LAC + USC Medical Center Los Angeles California 90033
USC Norris Comprehensive Cancer Center Los Angeles California 90033
USC/Norris Comprehensive Cancer Center Los Angeles California 90033
Keck Medical Center of USC Pasadena Pasadena California 91105
AdventHealth Celebration Infusion Center Celebration Florida 34747
AdventHealth Medical Group Oncology Research at Celebration Celebration Florida 34747
University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center Miami Florida 33136
AdventHealth Orlando - Investigational Drug Services Orlando Florida 32804
AdventHealth Orlando Infusion Center Orlando Florida 32804
AdventHealth Orlando Orlando Florida 32804
St. Joseph Mercy Hospital Ann Arbor Michigan 48106
St. Joseph Mercy Brighton Brighton Michigan 48114
Henry-Joyce Cancer Clinic Nashville Tennessee 37232
Oncology IDS Pharmacy Nashville Tennessee 37232
The University of Texas Houston Texas 77030
NEXT Oncology San Antonio Texas 78229
Inova Schar Cancer Institute Fairfax Virginia 22031
Seattle Cancer Care Alliance Seattle Washington 98109
University of Washington Medical Center Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03854227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2025 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03854227 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →